Compare Torrent Pharma with FDC LTD. - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

TORRENT PHARMA vs FDC LTD. - Comparison Results

TORRENT PHARMA     Change

Torrent Pharmaceuticals Ltd. is the flagship company of the Torrent Group set up in 1959. Based in Ahmedabad, it was promoted by Mr U.N. Mehta initially as Trinity Laboratories Ltd. and was later renamed to its current name. The company derives its r... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    TORRENT PHARMA FDC LTD. TORRENT PHARMA/
FDC LTD.
 
P/E (TTM) x 58.2 16.2 358.5% View Chart
P/BV x 6.2 2.2 280.1% View Chart
Dividend Yield % 0.8 0.0 -  

Financials

 TORRENT PHARMA   FDC LTD.
EQUITY SHARE DATA
    TORRENT PHARMA
Mar-18
FDC LTD.
Mar-18
TORRENT PHARMA/
FDC LTD.
5-Yr Chart
Click to enlarge
High Rs1,550319 485.9%   
Low Rs1,144164 697.3%   
Sales per share (Unadj.) Rs354.761.6 575.4%  
Earnings per share (Unadj.) Rs40.19.9 402.8%  
Cash flow per share (Unadj.) Rs64.212.0 536.8%  
Dividends per share (Unadj.) Rs14.000-  
Dividend yield (eoy) %1.00-  
Book value per share (Unadj.) Rs273.173.2 373.3%  
Shares outstanding (eoy) m169.22174.40 97.0%   
Bonus/Rights/Conversions -BB-  
Price / Sales ratio x3.83.9 96.9%   
Avg P/E ratio x33.624.3 138.4%  
P/CF ratio (eoy) x21.020.2 103.9%  
Price / Book Value ratio x4.93.3 149.4%  
Dividend payout %34.90-   
Avg Mkt Cap Rs m227,89742,118 541.1%   
No. of employees `00014.75.5 265.8%   
Total wages/salary Rs m11,3532,167 524.0%   
Avg. sales/employee Rs Th4,083.01,943.7 210.1%   
Avg. wages/employee Rs Th772.3391.7 197.1%   
Avg. net profit/employee Rs Th461.3313.7 147.1%   
INCOME DATA
Net Sales Rs m60,02110,751 558.3%  
Other income Rs m2,988510 586.4%   
Total revenues Rs m63,00911,260 559.6%   
Gross profit Rs m13,4932,267 595.2%  
Depreciation Rs m4,086351 1,162.8%   
Interest Rs m3,08514 22,034.3%   
Profit before tax Rs m9,3102,411 386.1%   
Minority Interest Rs m0-5 0.0%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m2,529671 376.7%   
Profit after tax Rs m6,7811,735 390.8%  
Gross profit margin %22.521.1 106.6%  
Effective tax rate %27.227.8 97.6%   
Net profit margin %11.316.1 70.0%  
BALANCE SHEET DATA
Current assets Rs m52,6237,213 729.6%   
Current liabilities Rs m52,0222,104 2,472.9%   
Net working cap to sales %1.047.5 2.1%  
Current ratio x1.03.4 29.5%  
Inventory Days Days12054 219.5%  
Debtors Days Days7628 274.9%  
Net fixed assets Rs m85,0166,865 1,238.4%   
Share capital Rs m846175 483.0%   
"Free" reserves Rs m45,37612,586 360.5%   
Net worth Rs m46,22212,761 362.2%   
Long term debt Rs m41,1156 685,243.3%   
Total assets Rs m142,43215,041 946.9%  
Interest coverage x4.0173.2 2.3%   
Debt to equity ratio x0.90 189,184.3%  
Sales to assets ratio x0.40.7 59.0%   
Return on assets %6.911.6 59.6%  
Return on equity %14.713.6 107.9%  
Return on capital %14.219.0 74.9%  
Exports to sales %012.3 0.0%   
Imports to sales %00-   
Exports (fob) Rs mNA1,327 0.0%   
Imports (cif) Rs mNANA-   
Fx inflow Rs m14,5801,889 771.9%   
Fx outflow Rs m3,6000-   
Net fx Rs m10,9801,889 581.3%   
CASH FLOW
From Operations Rs m8,9421,498 596.8%  
From Investments Rs m-47,070201 -23,406.0%  
From Financial Activity Rs m34,174-1,694 -2,017.0%  
Net Cashflow Rs m-3,65510 -35,485.4%  

Share Holding

Indian Promoters % 71.5 68.9 103.8%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 7.0 4.7 149.4%  
FIIs % 12.6 7.5 168.0%  
ADR/GDR % 0.0 0.0 -  
Free float % 8.8 19.0 46.3%  
Shareholders   26,511 23,730 111.7%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare TORRENT PHARMA With:   NATCO PHARMA  PANACEA BIOTECH  WOCKHARDT  GSK PHARMA  PLETHICO PHARMA  

Compare TORRENT PHARMA With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Indian Stock Markets Remain in Green This Week: Is the Rebound Here?(Podcast)

After a long period of underperformance, stock markets traded in green territory throughout the week. So, is this is a trend reversal and is the bottom forming in the market?

Related Views on News

FDC LTD. Announces Quarterly Results (1QFY20); Net Profit Up 2.4% (Quarterly Result Update)

Aug 6, 2019 | Updated on Aug 6, 2019

For the quarter ended June 2019, FDC LTD. has posted a net profit of Rs 523 m (up 2.4% YoY). Sales on the other hand came in at Rs 3 bn (up 17.9% YoY). Read on for a complete analysis of FDC LTD.'s quarterly results.

TORRENT PHARMA Announces Quarterly Results (1QFY20); Net Profit Up 32.5% (Quarterly Result Update)

Jul 25, 2019 | Updated on Jul 25, 2019

For the quarter ended June 2019, TORRENT PHARMA has posted a net profit of Rs 2 bn (up 32.5% YoY). Sales on the other hand came in at Rs 20 bn (up 8.0% YoY). Read on for a complete analysis of TORRENT PHARMA's quarterly results.

FDC LTD. Announces Quarterly Results (4QFY19); Net Profit Up 6.8% (Quarterly Result Update)

May 30, 2019 | Updated on May 30, 2019

For the quarter ended March 2019, FDC LTD. has posted a net profit of Rs 337 m (up 6.8% YoY). Sales on the other hand came in at Rs 3 bn (down 0.6% YoY). Read on for a complete analysis of FDC LTD.'s quarterly results.

TORRENT PHARMA Announces Quarterly Results (4QFY19); Net Profit Down 166.7% (Quarterly Result Update)

May 22, 2019 | Updated on May 22, 2019

For the quarter ended March 2019, TORRENT PHARMA has posted a net profit of Rs 2 bn (down 166.7% YoY). Sales on the other hand came in at Rs 19 bn (up 7.8% YoY). Read on for a complete analysis of TORRENT PHARMA's quarterly results.

FDC LTD. 2017-18 Annual Report Analysis (Annual Result Update)

Mar 28, 2019 | Updated on Mar 28, 2019

Here's an analysis of the annual report of FDC LTD. for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of FDC LTD.. Also includes updates on the valuation of FDC LTD..

More Views on News

Most Popular

My 3 Best Small-cap Stocks to Get Rich in this Market Rebound(Profit Hunter)

Oct 14, 2019

This is once in a decade opportunity to make a killing from smallcap rebound.

Finally, Is the Share Price of Yes Bank Ready for a Rebound?(The 5 Minute Wrapup)

Oct 7, 2019

Here's what every individual investor must know about Yes Bank...

Two Stocks to Buy in the Great Indian Festival(Profit Hunter)

Oct 11, 2019

Discounts are not just limited to E-tailers. You can buy stocks at 50% off too. Here are two stocks to buy now.

Buy these 3 Stocks for Rebound Riches

Oct 18, 2019

Equitymaster's smallcap guru and editor of Hidden Treasure, Richa Agarwal, talks to us about the rebound in the stock market, and the best stocks to profit from it. Listen in...

The One Stock I Like in this Market(The 5 Minute Wrapup)

Oct 10, 2019

There are rare periods in markets when you get good quality stocks at attractive valuations. Is this one such period?

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2020
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

TORRENT PHARMA SHARE PRICE


Oct 18, 2019 (Close)

TRACK TORRENT PHARMA

  • Track your investment in TORRENT PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON TORRENT PHARMA

TORRENT PHARMA 8-QTR ANALYSIS

COMPARE TORRENT PHARMA WITH

MARKET STATS